Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.

[1]  M. Dougados,et al.  Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. , 2006, Joint, bone, spine : revue du rhumatisme.

[2]  M. Dougados,et al.  Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. , 2006, Joint, bone, spine : revue du rhumatisme.

[3]  J. Sibilia,et al.  Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab , 2005, Annals of the rheumatic diseases.

[4]  F. Zoulim,et al.  Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. , 2005, Rheumatology.

[5]  M. Dougados,et al.  Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. , 2005, Joint, bone, spine : revue du rhumatisme.

[6]  K. Mackay,et al.  Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease. , 2005, Rheumatology.

[7]  T. Pincus,et al.  Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities , 2004, Annals of the rheumatic diseases.

[8]  P. Adeleine,et al.  Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[9]  F Guillemin,et al.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.

[10]  J. O'dell,et al.  Therapeutic strategies for rheumatoid arthritis. , 2004, The New England journal of medicine.

[11]  M. Kurosaki,et al.  Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. , 2004, Clinical and experimental rheumatology.

[12]  M. A. van de Laar,et al.  Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. , 2004, The Journal of rheumatology.

[13]  J. Kremer,et al.  Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[14]  V. Dhillon,et al.  Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[15]  C. Kelly,et al.  Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. , 2003, Rheumatology.

[16]  P. Emery,et al.  Parenteral methotrexate should be given before biological therapy. , 2003, Rheumatology.

[17]  L. Punzi,et al.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate , 2003, Annals of the rheumatic diseases.

[18]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[19]  G. Newsome.  Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.

[20]  D. Schapira,et al.  Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate , 2002, Annals of the rheumatic diseases.

[21]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[22]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[23]  B. Dijkmans,et al.  Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. , 2001, Arthritis and rheumatism.

[24]  A. Murasawa,et al.  Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. , 2001, Arthritis and rheumatism.

[25]  P. Jones,et al.  Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? , 2000, Rheumatology.

[26]  M. Yuen,et al.  Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. , 2000, Clinical and experimental rheumatology.

[27]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[28]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.

[29]  P. Shekelle,et al.  Clinical guidelines: developing guidelines. , 1999, BMJ.

[30]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[31]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[32]  C. Bologna,et al.  Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients , 1998, Annals of the rheumatic diseases.

[33]  J. Narváez,et al.  Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. , 1998, The Journal of rheumatology.

[34]  T. Mimori,et al.  Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. , 1997, The Journal of rheumatology.

[35]  J. Kremer,et al.  Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. , 1997, Arthritis and rheumatism.

[36]  M Macaluso,et al.  Risk Factors for Methotrexate-Induced Lung Injury in Patients with Rheumatoid Arthritis: A Multicenter, Case-Control Study , 1997, Annals of Internal Medicine.

[37]  S. van der Linden,et al.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis , 1997, The Lancet.

[38]  J. Kremer,et al.  Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. , 1997, British journal of rheumatology.

[39]  J. Kremer,et al.  Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. , 1996, The Journal of rheumatology.

[40]  L. Espinoza,et al.  Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[41]  Y. Maugars,et al.  Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) , 1995, Revue du rhumatisme.

[42]  R. Balk,et al.  The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. , 1995, The Journal of rheumatology.

[43]  G. Alarcón,et al.  Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[44]  P. Seideman.  Methotrexate--the relationship between dose and clinical effect. , 1993, British journal of rheumatology.

[45]  J. Esdaile,et al.  Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. , 1993, Arthritis and rheumatism.

[46]  M. Weinblatt,et al.  Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. , 1993, The Journal of rheumatology.

[47]  M. Weinblatt,et al.  The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. , 1993, Arthritis and rheumatism.

[48]  D. Mock,et al.  A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. , 1993, The Journal of rheumatology.

[49]  M. Hargreaves,et al.  Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. , 1992, Thorax.

[50]  D. M. Hoffman,et al.  Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. , 1991, Annals of the rheumatic diseases.

[51]  L. van de Putte,et al.  Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. , 1991, Annals of internal medicine.

[52]  P. Vacek,et al.  Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. , 1990, The Journal of rheumatology.

[53]  M. Sherman,et al.  Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. , 1990, Annals of internal medicine.

[54]  G. Alarcón,et al.  The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[55]  D. Furst,et al.  Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. , 1989, The Journal of rheumatology.

[56]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[57]  P. Meffin,et al.  Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? , 1988, The Journal of rheumatology.

[58]  A. Russell,et al.  Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. , 1988, The Journal of rheumatology.

[59]  G. Searles,et al.  Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. , 1987, The Journal of rheumatology.

[60]  D. Clegg,et al.  Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. , 1987, Seminars in arthritis and rheumatism.

[61]  M. Guttadauria,et al.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1985, Arthritis and rheumatism.

[62]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.